Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04175925 · ClinicalTrials.gov registry record · Phase 1
A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants
A Phase 1 study of Healthy Participants, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 171
- Enrollment target
- 1
- Study location
NCT04175925: Completed Phase 1 study of Healthy Participants, sponsored by Bristol-Myers Squibb.
NCT04175925 is a Phase 1 study of Healthy Participants that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 171 participants, above the 64-participant average among 119 other Healthy Participants trials with a reported enrollment target (167% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04175925, a Phase 1 study of Healthy Participants, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 171 participants
- Enrollment target
- 1
- Study location
Study Summary
A Study assessing the drug levels and drug effects of variable doses of BMS-986322 in Healthy Participants compared to a placebo. The study also assesses how BMS-986322 affects the body with food and its acidity levels.
Conditions Studied
Interventions
- DRUG famotidine
- DRUG BMS-986322
- OTHER BMS-986322 Placebo
Study Locations (1)
Kansas
- ICON (LPRA) - Lenexa - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2019-11-15 |
| Est. Completion | 2021-07-13 |
| Phase | Phase 1 |
What the finished NCT04175925 record still lists
NCT04175925 is an interventional study that assigns participants to a tested intervention. The registered 171 participants enrollment target is mid-sized for trials with a published cap, above the 64-participant average among 119 other Healthy Participants trials with a reported enrollment target (167% higher).
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 3 interventions - of which famotidine is the first listed.
NCT04175925 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT04175925 about?
NCT04175925 is a clinical study titled "A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants". A Study assessing the drug levels and drug effects of variable doses of BMS-986322 in Healthy Participants compared to a placebo. The study also assesses how BMS-986322 affects the body with food and its acidity levels.
What is the current status of trial NCT04175925?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 171 participants. The study started on 2019-11-15. Estimated completion is 2021-07-13.
What conditions does trial NCT04175925 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT04175925?
The interventions under investigation include: famotidine (DRUG), BMS-986322 (DRUG), BMS-986322 Placebo (OTHER).
Who is sponsoring clinical trial NCT04175925?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04175925 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04175925's enrollment target sits among peer trials
171 9th of 119 higher than 111 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02641145 · 171 participants · NA
Molecular Imaging of Primary Amyloid Cardiomyopathy
- NCT05541029 · 171 participants · NA
Music Listening: A Mechanistic Trial
- NCT05561127 · 171 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel
- NCT05592938 · 171 participants · NA
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI